Pfizer and Lilly announce tanezumab BLA accepted

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for tanezumab 2.5mg administered subcutaneously (SC) for patients with chronic pain due to moderate-to-severe osteoarthritis (OA), who have experienced inadequate relief with other analgesics.

Tanezumab is a monoclonal antibody being developed by US pharma companies Pfizer (NYSE: LLY) and Eli Lilly (NYSE: LLY) that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor inhibitors.

PDUFA of December this year